Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

P. Moreau, P. Sonneveld, M. Boccadoro, G. Cook, MV. Mateos, H. Nahi, H. Goldschmidt, MA. Dimopoulos, P. Lucio, J. Bladé, M. Delforge, R. Hajek, H. Ludwig, T. Facon, JFS. Miguel, H. Einsele,

. 2019 ; 104 (12) : 2358-2360. [pub] 20190822

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025432

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025432
003      
CZ-PrNML
005      
20201222160213.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.224204 $2 doi
035    __
$a (PubMed)31439675
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Moreau, Philippe $u University Hospital Hôtel-Dieu, Nantes, France philippe.moreau@chu-nantes.fr.
245    10
$a Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network / $c P. Moreau, P. Sonneveld, M. Boccadoro, G. Cook, MV. Mateos, H. Nahi, H. Goldschmidt, MA. Dimopoulos, P. Lucio, J. Bladé, M. Delforge, R. Hajek, H. Ludwig, T. Facon, JFS. Miguel, H. Einsele,
520    9_
$a Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.
650    _2
$a konsensus $7 D032921
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a mnohočetný myelom $x terapie $7 D009101
650    _2
$a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
650    _2
$a společnosti lékařské $7 D012955
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sonneveld, Pieter $u Erasmus Medical Center, Rotterdam, the Netherlands.
700    1_
$a Boccadoro, Mario $u Università di Torino/Azienda Ospedaliera San Giovanni, Torino, taly.
700    1_
$a Cook, Gordon $u Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
700    1_
$a Mateos, Ma Victoria $u University of Salamanca, Salamanca, Spain.
700    1_
$a Nahi, Hareth $u Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Goldschmidt, Hartmut $u Universitätsklinikum Heidelberg, Heidelberg, Germany.
700    1_
$a Dimopoulos, Meletios A $u University Athens School of Medicine, Athens, Greece.
700    1_
$a Lucio, Paulo $u Fundação Champalimaud, Lisbon, Portugal.
700    1_
$a Bladé, Joan $u Hospital Clinic de Barcelona, Barcelona, Spain.
700    1_
$a Delforge, Michel $u Department of Hematology, Catholic University of Leuven, Leuven, Belgium.
700    1_
$a Hajek, Roman $u University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, Wilhelminen, Austria.
700    1_
$a Facon, Thierry $u University Hospital Hurriez, Lille, France.
700    1_
$a Miguel, Jesus F San $u University of Navarra, Navarra, Spain.
700    1_
$a Einsele, Hermann $u University of Wurzburg, Wurzburg, Germany.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 12 (2019), s. 2358-2360
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31439675 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160209 $b ABA008
999    __
$a ok $b bmc $g 1599577 $s 1116118
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 12 $d 2358-2360 $e 20190822 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace